Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
One Percent Rule Checklist For Safer Forex Trading Risk 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Walmart International CEO Kathryn McLay to Step Down After Two and a Half Years 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Anthropic Appoints Former Microsoft Executive Irina Ghose to Lead India Expansion 
NEW YORK, April 20, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of Florida on behalf of investors who purchased TherapeuticsMD, Inc. ("TherapeuticsMD") (NYSEMKT:TXMD) securities between July 7, 2016 and April 9, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/therapeuticsmd-inc?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (i) the Company’s New Drug Application (NDA) submission for TX-004HR was deficient; (ii) the Company’s NDA submission for TX-004HR was not supported by the complete TX-004HR clinical program and/or the clinical program was deficient; (iii) the Company’s deficient NDA would likely cause a delay of the FDA’s potential approval of the TX-0004HR NDA.
If you suffered a loss in TherapeuticsMD you have until June 19, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/therapeuticsmd-inc?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
